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Dsequelae of VinV-TAVI, especially with regard to the effect
of high postprocedural valve gradients or durability, could
not be assessed.CONCLUSIONS
VinV-TAVI is a part of the armamentarium in most cen-
ters performing TAVI, albeit in small numbers. In this high-
risk patient population, the early experience has been excel-
lent, with a low incidence of device- or procedure-related
complications. However, a considerable number of patients
had a high transvalvular gradient after the procedure, the
long-term effects of which are unknown. Close long-term
surveillance after VinV-TAVI is needed, especially for pa-
tients known to have suboptimal systolic valve function.
Finally, future larger scale studies are warranted.
The authors thank Janne Jokinen from Helsinki University Hos-
pital (Helsinki, Finland) for his invaluable aid and review of the
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Discussion
Dr Mathew R. Williams (New York, NY). This is an exciting
procedure that really represents a sweet spot for transcatheter
valves. This is an observational study, your data is well presented,
and to that end I certainly do not have any critiques. However, I
would rather spend the time to discuss procedural and planning
components, because, fortunately now, a lot more of us are able
to do this procedure.
The first question is how have you decided what kind of access
to use in these patients? Initially, the reports suggested that this
should be done with a transapical approach. We have not found
that and have generally been just access driven.
Dr Ihlberg. I would say that the access is completely today up
to the discretion and preference of the operator and also partly for
the device used at the given center. My personal bias is that I still
like the surgical short access, good device maneuvering, and to be
able to land the device exactly on the target. I tend to conceptualize
the procedure as being similar to landing a helicopter onto an air
carrier. Needless to say, we do not have any air carriers in Finland,
and I have never done that myself, but it is just a concept. Still, I
like it, especially when you do valve in valve because of the sort
of small target in which you land it, but I know that, equally
well, people do this transfemorally.
DrWilliams. Is there any reason that this procedure works very
well? There is much less paravalvular leakage than we see in the
native aortic stenosis, which is really one of the Achilles heels
of this procedure. Is there any reason that in most patients this
should not quickly become the standard of care for degenerated tis-
sue valves, even in lower risk patients?
Dr Ihlberg. That is a great question or thought, and I think you
are correctly right in your considerations. I believe that things are
rapidly moving to that direction, so that valve-in-valve TAVImight
even become a default procedure under certain conditions. Thus, if
you do not have any pre-identified risk of coronary obstruction or if
you do not have a primary patient–prosthesis mismatch in these
patients, you can expect to have a reasonable gradient after the pro-
cedure. The results so far in our study and in the other studies, of
which the largest is the global valve-in-valve registry, have been
good.gery c November 2013
